Effects of the N-Methyl-D-aspartate Receptor AntagonistPerzinfotel [2][3][4][5][6][7][8] ABSTRACT Perzinfotel [2][3][4][5][6][7][8].0]non-1(7)-en-2-yl)-ethyl]phosphonic acid] is a selective, competitive Nmethyl-D-aspartate (NMDA) receptor antagonist with high affinity for the glutamate site. The current study evaluated whether perzinfotel would have antinociceptive effects or block thermal hypersensitivity associated with the administration of chemical irritants in rats. Perzinfotel lacked antinociceptive effects but dose-and time-dependently blocked prostaglandin E 2 (PGE 2 )-and capsaicin-induced thermal hypersensitivity in a warm-water tail-withdrawal assay in rats. Doses of 10 mg/kg intraperitoneal or 100 mg/kg oral blocked PGE 2 -induced hypersensitivity by 60 to 80%. The magnitude of reversal was greater than other negative modulators of the NMDA receptor studied, such as uncompetitive channel blockers (e.g., memantine, dizocilpine, and ketamine), a NR2B selective antagonist (e.g., ifenprodil), and other glutamate antagonists [e.g., selfotel, 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid (CPP), D,L-(E)-2-amino-4-propyl-5-phosphono-3-pentenoic acid (CGP-39653)], up to doses that suppressed operant rates of responding. In contrast to other negative modulators of the NMDA receptor studied, which typically decreased operant rates of responding at doses that lacked antinociceptive effects, perzinfotel did not modify response rates at doses that blocked irritant-induced thermal hypersensitivity. Collectively, these studies demonstrate that perzinfotel has therapeutic ratios for effectiveness versus adverse effects superior to those seen with other competitive and uncompetitive NMDA receptor antagonists studied.Excitatory amino acids acting at NMDA receptors play a role in both acute and chronic pain. Increases in afferent input and glutamate release within the spinal cord have been observed after peripheral injection of an irritant (e.g., carrageenan) or tissue injury (Sluka and Westlund, 1993;Kawamata and Omote, 1996;Dickenson et al., 1997). Repeated stimulation of primary afferent fibers can progressively increase the magnitude and duration of action potentials in spinal cord (often termed "windup"), which can lead to central sensitization (Ma and Woolf, 1995). This neuronal hyperexcitability manifests itself in a lowered threshold to evoked activity (i.e., hyperalgesia), an expansion of receptive fields (i.e., secondary hypersensitivity), and an ability of non-noxious input to evoke neuronal activity (i.e., allodynia). In preclinical studies, NMDA receptor antagonists reverse neuronal hyperexcitability and reverse hypersensitivity in several inflammatory and neuropathic animal pain models associated with various pathophysiologic mechanisms (Mao et al., 1993;Chaplan et al., 1997;Suzuki et al., 2001). In clinical studies, NMDA receptor antagonists, such as ketamine and dextromethorphan, reduce windup pain, spontaneous pain, hyperalgesia, and allodynia in patients with postherpetic neuralgia pain, phantom ...